VYGR's three largest insider shareholders as of March 23, 2026 are Biosciences Inc Neurocrine (TenPercentOwner, 8.58Mn shares), Capital, Llc Ecor1 (TenPercentOwner, 3.85Mn shares), Rock Ventures Iii, L.P. Third (TenPercentOwner, 3.19Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Biosciences Inc Neurocrine | 8,575,316 | 0 | 24 Feb, 2022 | |
| Capital, Llc Ecor1 | 0 | 3,851,507 | 11 Jan, 2023 | |
| Rock Ventures Iii, L.P. Third | 3,185,291 | 0 | 06 Feb, 2023 | |
| Alfred Sandrock | President And Ceo | 484,060 | 0 | 26 Feb, 2026 |
| Robin Swartz | Coo Cbo | 199,738 | 0 | 26 Feb, 2026 |
| Toby Ferguson | Chief Medical Officer | 183,914 | 0 | 10 Feb, 2026 |
| Peter P. Pfreundschuh | Chief Financial Officer | 175,669 | 0 | 22 Feb, 2024 |
| Nathan D. Jorgensen | Chief Financial Officer | 151,416 | 0 | 26 Feb, 2026 |
| Todd Alfred Carter | Chief Scientific Officer | 145,718 | 0 | 26 Feb, 2026 |
| Sandell Jacquelyn Fahey | Chief Legal Officer | 123,143 | 0 | 24 Feb, 2025 |
| Omar Khwaja | See Remarks | 120,509 | 0 | 25 May, 2021 |
| Robert W. Hesslein | Senior Vp General Counsel | 102,200 | 0 | 22 Mar, 2023 |
| Julie Burek | Vp, Finance | 52,458 | 0 | 23 Mar, 2022 |
| Michael J Higgins | 31,314 | 0 | 18 Jul, 2022 | |
| Glenn Pierce | 16,788 | 0 | 18 Jul, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 24 Feb, 2026 | Nathan D. Jorgensen | Common Stock | D | 4,668 | $3.77 | 151,416 | D | S |
| 24 Feb, 2026 | Robin Swartz | Common Stock | D | 6,458 | $3.77 | 199,738 | D | S |
| 24 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 4,174 | $3.76 | 145,718 | D | S |
| 24 Feb, 2026 | Alfred Sandrock | Common Stock | D | 14,197 | $3.79 | 484,060 | D | S |
| 18 Feb, 2026 | Robin Swartz | Common Stock | D | 3,882 | $3.44 | 206,196 | D | S |
| 18 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 3,301 | $3.44 | 149,892 | D | S |
| 18 Feb, 2026 | Alfred Sandrock | Common Stock | D | 11,732 | $3.41 | 498,257 | D | S |
| 10 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 3,525 | $3.85 | 153,193 | D | S |
| 10 Feb, 2026 | Robin Swartz | Common Stock | D | 4,569 | $3.85 | 210,078 | D | S |
| 10 Feb, 2026 | Alfred Sandrock | Common Stock | D | 12,192 | $3.78 | 509,989 | D | S |
| 06 Feb, 2026 | Robin Swartz | Common Stock | A | 45,000 | $0.00 | 214,647 | D | A |
| 06 Feb, 2026 | Todd Alfred Carter | Common Stock | A | 33,000 | $0.00 | 156,718 | D | A |
| 06 Feb, 2026 | Toby Ferguson | Common Stock | A | 45,000 | $0.00 | 183,914 | D | A |
| 06 Feb, 2026 | Alfred Sandrock | Common Stock | A | 86,250 | $0.00 | 522,181 | D | A |
| 06 Feb, 2026 | Nathan D. Jorgensen | Common Stock | A | 32,250 | $0.00 | 156,084 | D | A |
| 06 Feb, 2026 | Nathan D. Jorgensen | Stock Option (Right to Buy) | A | 150,500 | $0.00 | 150,500 | D | A |
| 06 Feb, 2026 | Toby Ferguson | Stock Option (Right to Buy) | A | 210,000 | $0.00 | 210,000 | D | A |
| 06 Feb, 2026 | Todd Alfred Carter | Stock Option (Right to Buy) | A | 154,000 | $0.00 | 154,000 | D | A |
| 06 Feb, 2026 | Robin Swartz | Stock Option (Right to Buy) | A | 210,000 | $0.00 | 210,000 | D | A |
| 06 Feb, 2026 | Alfred Sandrock | Stock Option (Right to Buy) | A | 402,500 | $0.00 | 402,500 | D | A |